Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches

John H. Strickler, Christina Wu, Tanios Bekaii-Saab

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.

Original languageEnglish (US)
Pages (from-to)109-119
Number of pages11
JournalCancer Treatment Reviews
Volume60
DOIs
StatePublished - Nov 1 2017

Fingerprint

Proto-Oncogene Proteins B-raf
Colorectal Neoplasms
Molecular Epidemiology
Therapeutics
Mutation
Survival
Population

Keywords

  • BRAF
  • Colorectal cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Targeting BRAF in metastatic colorectal cancer : Maximizing molecular approaches. / Strickler, John H.; Wu, Christina; Bekaii-Saab, Tanios.

In: Cancer Treatment Reviews, Vol. 60, 01.11.2017, p. 109-119.

Research output: Contribution to journalReview article

@article{c3e408f6c45441918ae9fcf1ad8ed291,
title = "Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches",
abstract = "Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10{\%} of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.",
keywords = "BRAF, Colorectal cancer, Targeted therapy",
author = "Strickler, {John H.} and Christina Wu and Tanios Bekaii-Saab",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.ctrv.2017.08.006",
language = "English (US)",
volume = "60",
pages = "109--119",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Targeting BRAF in metastatic colorectal cancer

T2 - Maximizing molecular approaches

AU - Strickler, John H.

AU - Wu, Christina

AU - Bekaii-Saab, Tanios

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.

AB - Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.

KW - BRAF

KW - Colorectal cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85029820079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029820079&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2017.08.006

DO - 10.1016/j.ctrv.2017.08.006

M3 - Review article

C2 - 28946014

AN - SCOPUS:85029820079

VL - 60

SP - 109

EP - 119

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -